ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.76
0.00%
US Dollar vs AUD
1.49209
0.00%
Bitcoin
66,938.93
-0.21%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Elevation Oncology Inc (ELEV)

  7. Elevation Oncology Inc (ELEV) News

ELEV

Elevation Oncology (ELEV)

Elevation Oncology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ELEV
DateTimeSourceHeadlineSymbolCompany
18/05/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
10/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELEVElevation Oncology Inc
10/05/202406:39Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELEVElevation Oncology Inc
07/05/202421:30PR Newswire (US)Elevation Oncology to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:ELEVElevation Oncology Inc
02/05/202421:30PR Newswire (US)Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
09/04/202406:30PR Newswire (US)Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
07/03/202400:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELEVElevation Oncology Inc
06/03/202423:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
06/03/202423:30PR Newswire (US)Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/03/202423:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ELEVElevation Oncology Inc
06/03/202408:50PR Newswire (US)Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
05/03/202408:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
05/03/202408:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
04/03/202423:30PR Newswire (US)Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
28/02/202423:30PR Newswire (US)Elevation Oncology to Participate in Upcoming Investor ConferencesNASDAQ:ELEVElevation Oncology Inc
22/02/202423:30PR Newswire (US)Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanNASDAQ:ELEVElevation Oncology Inc
21/02/202409:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
21/02/202408:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
21/02/202408:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
15/02/202408:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELEVElevation Oncology Inc
24/01/202408:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
23/01/202408:57Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELEVElevation Oncology Inc
23/01/202408:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
23/01/202408:24Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
22/01/202423:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
22/01/202423:30PR Newswire (US)Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
10/01/202408:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELEVElevation Oncology Inc
05/01/202423:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
05/01/202423:30PR Newswire (US)Elevation Oncology Announces Program Updates and Upcoming 2024 MilestonesNASDAQ:ELEVElevation Oncology Inc
22/11/202323:30PR Newswire (US)Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:ELEVElevation Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:ELEV

Your Recent History

BIT
GS0212
GOLDMAN SACHS
BIT
UV8CQ5
UniCredit Bank
BOV
RAPT3
RANDON PART ON
MRTX
EXRNETH
EXRNchain
TG
HFG
HelloFresh
XE
HYQ
Hypoport
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved